LEADER 02913nam 2200625Ia 450 001 9910457955003321 005 20200520144314.0 010 $a0-19-174042-X 010 $a0-19-960754-0 010 $a1-283-34836-5 010 $a9786613348364 010 $a0-19-157602-6 035 $a(CKB)2550000000064695 035 $a(EBL)797734 035 $a(OCoLC)761693525 035 $a(SSID)ssj0000534029 035 $a(PQKBManifestationID)11317580 035 $a(PQKBTitleCode)TC0000534029 035 $a(PQKBWorkID)10491781 035 $a(PQKB)10971647 035 $a(MiAaPQ)EBC797734 035 $a(StDuBDS)EDZ0000091499 035 $a(Au-PeEL)EBL797734 035 $a(CaPaEBR)ebr10511354 035 $a(CaONFJC)MIL334836 035 $a(EXLCZ)992550000000064695 100 $a20100113d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntibacterial chemotherapy$b[electronic resource] $etheory, problems and practice /$fby Sebastian G.B. Amyes 210 $aOxford ;$aNew York $cOxford University Press$d2010 215 $a1 online resource (93 p.) 225 1 $aOxford infectious diseases library 300 $aIncludes index. 311 $a0-19-958136-3 327 $aContents; Dedication; Preface; Abbreviations; 1 Antibiotic action-general principles; 2 Antibiotics-mechanisms of action; 3 Pharmacokinetics applied to antimicrobials; 4 Sensitivity and identification tests; 5 Genetics of antibiotic resistance; 6 Mechanisms of antibiotic resistance; 7 Multi-drug resistant (MDR) bacteria and healthcare-acquired infections; 8 Anti-mycobacterium therapy; 9 Clinical use of antibiotics to prevent or control resistance; Index; A; B; C; D; E; F; G; H; I; K; L; M; N; O; P; Q; R; S; T; U; V; Y 330 $aAlthough antibiotics are among the most widely used pharmaceuticals, they are also often inappropriately and over-prescribed. Indeed there are increasing predictions that unless we moderate our use of these drugs, bacterial resistance will eventually render them useless. As there are no serious contenders to take the place of antibiotics, including a failure to find new classes of these drugs, it is essential for modern medicine that their efficacy is preserved.Part of the Oxford Infectious Disease Library, this pocketbook is designed to help medical trainees, general prescribers, healthcare w 410 0$aOxford infectious diseases library. 606 $aAntibacterial agents 606 $aBacterial diseases 608 $aElectronic books. 615 0$aAntibacterial agents. 615 0$aBacterial diseases. 676 $a615.329 700 $aAmyes$b Sebastian G. B$0969443 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910457955003321 996 $aAntibacterial chemotherapy$92203008 997 $aUNINA LEADER 02748nam 2200661 a 450 001 9910969293803321 005 20260127005040.0 010 $a9786611284558 010 $a9781281284556 010 $a1281284556 010 $a9780470225806 010 $a0470225807 035 $a(CKB)1000000000409601 035 $a(EBL)335720 035 $a(OCoLC)437204773 035 $a(SSID)ssj0000130760 035 $a(PQKBManifestationID)11148787 035 $a(PQKBTitleCode)TC0000130760 035 $a(PQKBWorkID)10097765 035 $a(PQKB)11514435 035 $a(Au-PeEL)EBL335720 035 $a(CaPaEBR)ebr10295886 035 $a(CaONFJC)MIL128455 035 $a(FINmELB)ELB177471 035 $a(MiAaPQ)EBC335720 035 $a(Perlego)2756181 035 $a(EXLCZ)991000000000409601 100 $a20070712d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCorpocracy $ehow CEOs and the business roundtable hijacked the world's greatest wealth machine--and how to get it back /$fRobert A.G. Monks 205 $a1st ed. 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2008 215 $a1 online resource (274 p.) 300 $aDescription based upon print version of record. 311 08$a9780470145098 311 08$a0470145099 320 $aIncludes bibliographical references (p. 237-240) and index. 327 $aAn audience with the emperor -- Economics ascendant -- The Godfather -- The business roundtable -- Inside the corpocracy -- House take -- Efficiencies "R" us -- Return of the blob -- The great and the good -- Still, I dare to dream. 330 $aShareholder control over large corporations is worryingly weak and the unrestrained hunt for profits is taking a toll on the environment and society. In Corpocracy, corporate lawyer, venture capitalist, and shareholder activist Robert Monks reveals how corporations abuse their power and what we the people must do to rein them in. In a clear and careful analysis, Monks outlines a plan for reconciling the competing interests of corporations and society through thoughtful shareholder activism. 606 $aCorporations$xMoral and ethical aspects 606 $aChief executive officers$xMoral and ethical aspects 606 $aCorporate governance 615 0$aCorporations$xMoral and ethical aspects. 615 0$aChief executive officers$xMoral and ethical aspects. 615 0$aCorporate governance. 676 $a174/.4 700 $aMonks$b Robert A. G.$f1933-$0321741 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910969293803321 996 $aCorpocracy$94351617 997 $aUNINA